MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Core Viewpoint - Investors in MoonLake Immunotherapeutics have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company regarding its products and clinical benefits [1][3]. Summary by Sections Lawsuit Details - The lawsuit alleges that from March 10, 2024, to September 29, 2025, the defendants failed to disclose critical information about the company's products, specifically that SLK and BIMZELX share the same molecular targets, and that SLK's unique Nanobody structure does not provide superior clinical benefits compared to BIMZELX [3]. Investor Participation - Investors who suffered losses in MoonLake Immunotherapeutics are encouraged to contact the Law Offices of Howard G. Smith before December 15, 2025, to participate in the ongoing securities fraud lawsuit [2][4]. Legal Rights - Investors have the option to retain counsel of their choice or remain absent members of the class action without taking any immediate action [5].